MedTrace Logo

Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis

NCT02865876 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2016-08-15

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy and safety of accelerated cross-linking (Avedro Inc., Waltham, USA) in the management of microbial keratitis as adjunctive therapy.

Conditions

  • Keratitis

Interventions

PROCEDURE

Accelerated Corneal Cross-linking

All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.

Sponsors & Collaborators

  • Asociación para Evitar la Ceguera en México

    collaborator OTHER

  • Instituto de Oftalmología Fundación Conde de Valenciana

    lead OTHER

Principal Investigators

  • Enrique Graue-Hernandez, MSc · Instituto de Oftalmologia Fundacion Conde de Valenciana

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-08-31
Completion
2017-03-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02865876 on ClinicalTrials.gov